We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The European Commission has blessed the first biosimilar of Amgen’s blockbuster drug Enbrel, clearing the way for Samsung Bioepis to release the biosimilar in select EU countries in the coming weeks.